UOC
HUMA icon

UBS O'Connor’s Humacyte HUMA Stock Holding History

UBS O'Connor’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-595,172
Closed -$1.94M – 150
2022
Q3 		$1.94M Sell
595,172
-504,828
-46% -$1.94M 0.02% 632
2022
Q2 		$3.53M Buy
+1,100,000
New +$6.12M 0.04% 432
2022
Q1 		– Sell
-900,100
Closed -$6.53M – 97
2021
Q4 		$6.53M Buy
+900,100
New +$8.9M 0.06% 142
2021
Q3 		– Sell
-300,000
Closed -$3.06M – 950
2021
Q2 		$3.06M Sell
300,000
-3,800
-1% -$39.1K 0.03% 380
2021
Q1 		$3.29M Buy
+303,800
New +$3.32M 0.05% 364

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS O'Connor's HUMA Position: Q4 2022 in Review

UBS O'Connor sold out of Humacyte (HUMA) in Q4 2022, closing a stake of 595,172 shares — an estimated $1.94M sold.

UBS O'Connor first reported a position in HUMA in Q1 2021 and held it in 5 quarters. The position peaked at $6.53M in Q4 2021. 75 funds tracked by Wall St. Rank hold HUMA as of Q4 2022.

  • UBS O'Connor reported no remaining Humacyte position as of Q4 2022 after selling out during the quarter.
  • UBS O'Connor sold 595,172 Humacyte shares in Q4 2022, an estimated $1.94M.
  • UBS O'Connor first reported a position in Humacyte in Q1 2021 and held it in 5 quarters.
  • UBS O'Connor's Humacyte position peaked at $6.53M in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Humacyte as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.